Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Melanoma 33Thyroid Neoplasms 9Neoplasms 8Thyroid Carcinoma, Anaplastic 7Thyroid Cancer, Papillary 4Neoplasm Metastasis 4Multiple Myeloma 4Colorectal Neoplasms 4Ameloblastoma 4Hematologic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Skin Neoplasms 2Lymphoma, Non-Hodgkin 2Glioma 2Adenocarcinoma, Follicular 2Unspecified Adult Solid Tumor, Protocol Specific 1Thyroid cancer, follicular 1Thyroid cancer, Hurthle cell 1Thrombocytosis 1Spinocerebellar Degenerations 1Solid Tumor 1Sexual Dysfunction, Physiological 1Rare Malignant Neoplasm 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms by Site 1

Interventions

trametinib 1selpercatinib 1pralsetinib 1lenvatinib 1larotrectinib 1entrectinib 1dabrafenib 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Advanced Thyroid Cancer Patients Who Received Target Therapy × dabrafenib × Clear all
NCT06195228 2025-08-14

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Fudan University

Phase 4 Recruiting
800 enrolled
EndocrineHead & Neck

Advanced Thyroid Cancer Patients Who Received Target Therapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡